Search Results 2001-2010 of 20073 for Receptor

  1. Jill J. Colglazier, M.D. - Doctors and Medical Staff - Mayo Clinic

    Phagocytosis entails the recognition and engulfment of microbes by numerous cell surface receptors. Particle recognition is accompanied by polymerization of ...

  2. A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease - Mayo Clinic

    On a clinically relevant and stable dose of an angiotensin converting-enzyme inhibitor (ACEI) OR an angiotensin receptor blocker (ARB), unless not tolerated or ...

  3. Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions - Mayo Clinic

    ... receptor 2 (FGFR2). Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Participation ...

  4. Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure - Mayo Clinic

    Current use of a thrombopoietin receptor agonist (e.g., eltrombopag or romiplostim). Subject has an active infection requiring systemic antibiotic therapy ...

  5. Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma - Mayo Clinic

    ... receptor (e.g., CTLA-4, OX 40, CD137); any other checkpoint inhibitor; bevacizumab; or any prior vaccine therapy. Note: Other inclusion and exclusion ...

  6. A Study to Evaluate the Safety and Effectiveness of SPR001 in Adults with Classic Congenital Adrenal Hyperplasia - Mayo Clinic

    or any other CRF1 receptor antagonist - Current treatment with dexamethasone as GC therapy for CAH. Prior treatment with dexamethasone is allowed as long as ...

  7. FORTIFI-HN01: A Study Of Ficerafusp Alfa (BCA101) Or Placebo In Combination With Pembrolizumab In First-Line PD-L1-pos, R Or M HNSCC - Mayo Clinic

    Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to ...

  8. A Phase 1/2 Study to Evaluate MEDI4736 - Clinical Trials

    Prior treatment with immunotherapy agents including, but not limited to, tumor necrosis factor receptor superfamily agonists or checkpoint inhibitors or natural ...

  9. Neurosciences Clinical Trials - Medical Professionals

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  10. Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer - Mayo Clinic

    Exceptions: Individuals who use prescription PPIs and have approval from their primary health care provider to replace the PPI with an H2 receptor agonist ...